Subscribe to our Newsletters !!
Drug quality is defined not only how a drug is man
Eppendorf is launching the new VisioNize® box 2,
The journey and merging of sperm and egg cells is
This year, the Hamburg based life sciences company
Alembic Pharmaceutica
Since it’s an ingredient in so many foods, you h
Dear Readers,Welcome to the latest issue of Microb
Britain’s GlaxoSmithKline and France’s Sanofi on Monday said they had started a new clinical trial of their protein-based COVID-19 vaccine candidate and aim to get to the final testing phase in the second quarter.
If the results are conclusive, both drugmakers hope to find the vaccine approved by the fourth quarter after having originally targeted the first half of this year.
The move comes after the drugmakers in December said their vaccine could be delayed after clinical trials showed an inadequate immune response in older people.
The new trial will aim at evaluating the safety, tolerability and immune response of the vaccine in 720 healthy adults across the United States, Honduras and Panama, the companies said.
Sanofi and GSK’s candidate utilizes the exact recombinant protein-based technology among Sanofi’s seasonal flu vaccines. It’ll be combined with an adjuvant, a substance that acts as a booster to the shot, made by GSK.
The study will examine two injections given 21 days apart.
